ABT · 8-K · 20261021PR117587
Acquisition / Partnership / Divestiture
ABBOTT LABORATORIES · 2026-10-21 · Importance 71 · Surprise 60
Abbott intends to separate its global Nutrition business into an independent, publicly traded company through a tax-free distribution of shares to Abbott shareholders. The transaction is expected to be completed by the end of 2027, subject to regulatory approvals, a Form 10 registration statement becoming effective, and final Abbott Board approval. The Nutrition company will include the Similac, PediaSure, Pedialyte, Glucerna and Ensure brands, approximately 16,000 employees and 14 manufacturing sites. Abbott expects to incur one-time transaction charges before separation, but has not yet quantified them.